Improved Biocompatibility of Amino-Functionalized

Graphene Oxide in Caenorhabditis elegans by Rive, Corvin et al.
www.small-journal.com
1902699 (1 of 11) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Full PaPer
Improved Biocompatibility of Amino-Functionalized 
Graphene Oxide in Caenorhabditis elegans
Corvin Rive, Giacomo Reina, Prerana Wagle, Emanuele Treossi, Vincenzo Palermo, 
Alberto Bianco, Lucia Gemma Delogu, Matthias Rieckher,* and Björn Schumacher*
DOI: 10.1002/smll.201902699
and specifically its derivative graphene 
oxide (GO), is poised to play a central role in 
the future of nanomedicine, as it combines 
a number of advantageous chemical proper-
ties, including a large surface area that can 
be easily functionalized, high chemical sta-
bility, amphipathicity, and high thermal and 
electric conduction. Hence, GO holds great 
promise to be employable for drug delivery, 
tissue-engineering, biomedical imaging 
and diagnostics in human disease.[4,5] A 
rising number of recent studies focuses 
on the design of GO, GO composites, or 
functionalized GO, and their application 
in anticancer drug delivery, tumor detec-
tion, and ablation of cancerous tissue.[6–11] 
Importantly, there is indication that few 
layer graphene directly triggers necrotic cell 
death in monocytic cancer cells through an 
unknown mode-of-action, while other cell 
populations stay unharmed.[12]
In this context, the question about toxi city 
and immune compatibility becomes central 
for future nanomedical applications of graphene-based materials 
including GO, which has been addressed in an increasing amount 
of studies.[13] When injected into the blood stream, or adminis-
tered through the airway, acute GO exposure at high doses can 
cause pulmonary inflammation, cardiovascular and systemic tox-
icity in mice and rats.[14] GO can also adversely affect fecundity; 
some studies report toxi city to germ cells and reduced fertility in 
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1. Introduction
The advent of nanotechnology has advanced the development 
of innovative biomedical research tools and therapeutic clinical 
applications in nanomedicine.[1,2] Graphene is a unique nano-
material that is defined as a flat monolayer of carbon atoms, 
which are organized into a 2D honeycomb sp2 lattice.[3] Graphene, 
© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. 
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male mice that might depend on elevated cellular reactive oxygen 
species contents and subsequent DNA damage induction that in 
turn triggers apoptosis.[15,16] Accordingly, GO exposure can cause 
an immune response, involving the activation of macrophages and 
various interleukins, as well as neutrophil extracellular trap for-
mation similar to pathogen exposure.[17–19] The degree of toxicity 
and immune response activation that is observed across studies 
depend on the GO synthesis protocol and the resulting variability 
of physicochemical properties, which is determined by the lateral 
sheet size, vacancy or lattice defects, chemical purity and specific 
surface functionalization.[13,20–22] In cell culture, surface func-
tionalization or coating with organic compounds, or metals, has 
been shown to improve GO biocompatibility by reducing toxicity 
and immune response activation.[23–25] Single-cell mass cyto-
metry combined with whole-transcriptomic analysis revealed that 
amino-functionalized GO (GONH2) causes reduced metabolic per-
turbations in immune cells when compared to GO.[26] However, 
it remains unknown, whether GO or GONH2 treatment might 
adversely affect a whole-organism.
The genetically tractable nematode C. elegans has proven to be an 
informative model when it comes to understanding the mode-of-
actions and toxicity of organic compounds or nano materials.[27–29] 
Stress response mechanisms, including signaling pathways that 
regulate the innate immune response, are well-conserved in 
C. elegans, and protect the animals from environmental stress, 
pathogens, viruses, toxins and heavy metals, making the worm 
a powerful model for complex human diseases.[30,31] In recent 
years, the possible adverse effects of graphene on C. elegans have 
been investigated, resulting in considerable variations between 
the studies when measuring fecundity, development and lifespan, 
which might depend on the differences between the GO synthesis 
protocols and the specific treatment paradigm.[32–35]
In this work, we exposed C. elegans to small size GO and 
derived GONH2 under two regimens: acute (12 h) and chronic 
treatment (72 h). We characterized fecundity, developmental 
timing, physiology and lifespan, and found comparatively mild 
adverse effects upon chronic GO exposure, which were not 
detected upon exposure to amino-functionalized graphene oxide. 
Further, we performed RNA-Seq of whole-animal populations 
to resolve the response on a transcriptome-level upon acute GO 
treatment and found a mild but significant upregulation of the 
innate immune response, which was less pronounced upon 
GONH2. The response to GO depends on the conserved PMK-1 
p38 MAP kinase pathway that governs the innate immune 
response in the nematode. The adverse effects caused by gra-
phene could be suppressed upon genetic germline depletion in 
C. elegans. Overall, our study provides evidence that GO exposure 
causes systemic physiological damage, when combined with 
other genetic and environmental stressors, which is robustly 
reduced when exposed to amino-functionalized graphene.
2. Results
2.1. GO Synthesis and Characterization
Graphene oxide was synthesized via a modified Hummers′ 
method. The starting solution (2.5 g L−1) was then sonicated 
for 40 h and diluted to reach the desired concentrations.[36]  
The obtained GO has a size of 124±26 nm, calculated from 
the analysis of atomic force microscopy (AFM) images 
(Figure S1A,B, Supporting Information). Subsequently, amino-
functionalized GO was prepared by epoxide ring opening, as pre-
viously described.[37] Briefly, 2,2-(ethylenedioxy)bis(ethylamine) 
was grafted onto the sheets to form amino-functionalized 
GONH2. This amination reaction was performed in mild con-
ditions and in water to avoid any undesired effect of organic 
solvents. To remove the unreacted diamine, GONH2 was puri-
fied gently through extensive dialysis. Transmission electron 
microscopy (TEM) of GONH2 shows that the morphology and 
the lateral size of the nanosheets is preserved (Figure S1C, Sup-
porting Information). Additionally, little agglomeration was 
found in the case of GONH2 flakes. Fourier-transform infrared 
spectroscopy (FTIR) characterization of GO displays the typical 
broad band of the OH stretching at 3370 cm−1, and two sharp 
bands at 1708 and 1625 cm−1 attributed to the carbonyl and 
CC stretching, respectively (Figure S1D, Supporting Informa-
tion). The functionalization clearly modified the infrared spec-
trum of the material. The NH stretching bands at 3370 and 
3220 cm−1 overlap with the OH stretching. In addition, the 
band at 1625 cm−1 appears more intense together with the 
band at 1078 cm−1, corresponding to the NH bending and 
CN stretching, respectively. The new bands visible at 2910 
and 1360 cm−1 have been associated with the CH2 stretching 
and bending, respectively. Thermogravimetric profile of GO 
(Figure S1E, Supporting Information) shows a typical trend 
with a first mass loss below 100 °C ascribed to the desorption of 
adsorbed water and unstable oxygenated groups, a second loss 
around 200 °C due to the decomposition of more stable oxygen-
ated groups.[37] GONH2 presents a less significant thermal loss, 
which has been attributed to the instability of some oxygenated 
group present on the GO surface that are depleted during the 
amination reaction.[38] The Kaiser test confirmed the presence 
of free amines on the GO surface. Amination reaction produced 
the increase of the percentage of nitrogen from 0.59 ± 0.03 for 
GO to 3.2 ± 0.2 for GONH2 as atomic N%, which was assessed 
by X-Ray photoelectron spectroscopy (XPS).
2.2. Effects of GO on C. elegans Physiology
We designed two treatment paradigms to expose wild type 
C. elegans with GO flakes, or GONH2: acute treatment, which 
was applied from the larval stage 4 (L4) to young adulthood 
(12 h), and chronic treatment that started at L1 of development 
until day 1 of adulthood (72 h; see the Experimental Section; 
Figure 1A). We performed initial tests using 1, 10, 100, and 
200 µg mL−1 concentration of GO and GONH2 acute treat-
ments but initial assessment did not reveal any adverse effects 
on animal development, morphology, offspring number or 
movement on plates (data not shown). However, chronic GO 
treatments at 100 and 200 µg mL−1 led to an obvious size dif-
ference and reduced brood size. For a quantitative analysis we 
focused on the concentration of 100 µg mL−1 thereon.
The C. elegans germline commences proliferation of the 
somatic gonad and the germ cells at mid-L1 stage until a fully 
functional germline is established in adults, finalizing in the 
production of ≈300 offspring.[39] Adverse effects on egg laying 
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and hatching rates can be indicative of defects in somatic gonad 
development, or damage to the germ cells, oocytes or the devel-
oping embryo.[40] Indeed, chronic GO treatment resulted in a sig-
nificantly reduced egg-laying rate, which was not observed in the 
acute treatment regime or upon exposure to GONH2 (Figure 1B). 
The hatching rate was 100% in all treatments (data not shown). 
Chronic treatment with GO resulted in decreased animal size, 
which was not the case upon GONH2 exposure (Figure 1C). The 
size differences prompted us to investigate animal development 
in greater detail. Developmental timing is tightly regulated and 
highly reproducible in C. elegans, and the different developmental 
stages, from the embryo, through the four larval stages (L1 to L4) 
to adults (Figure 1A), are easily quantified at the stereoscope.[40] 
The analysis of animal development at 24, 48, and 72 h time 
points did not reveal any significant differences after chronic 
exposure (Figure S2, Supporting Information).
We continued our analysis by quantifying post-develop-
mental somatic phenotypes, including locomotion, pharyngeal 
pumping rates and longevity (Figure 1D–F). We applied worm-
tracking software to analyze recordings of animal movement[41] 
after acute treatment with GO or GONH2, and determined 
that the average speed of animals roaming on the plate was 
Small 2019, 15, 1902699
Figure 1. The effects of GO or GONH2 upon acute or chronic exposure. All experiments were performed at 20 °C. A) Developmental timing of C. elegans 
(at 20 °C) and the two treatment paradigms used in this study. Acute treatment was performed from mid-L4 stage to young adults (12 h), while chronic 
treatment was performed from L1 stage to 1 d adults (72 h). B) Egg-laying measurement. Significance against the control was determined by the 
unpaired t-test, with *p < 0.05. Chronic GO treatment reduced wild type egg-laying in two out of three experiments. C) Size measurement (perimeter). 
Statistical analysis was performed by using the Mann–Whitney test with ****p < 0.0001. Outliers are displayed according to the Tukey test (connected 
Figure S2, Supporting Information). D) Locomotion measurement. Significance test via Mann–Whitney analysis, with *p < 0.05, ****p < 0.0001. 
Outliers are displayed according to the Tukey analysis. E) Pumping rates of animals after acute or chronic treatment. Significance was determined 
via the unpaired Mann–Whitney test, in comparison to the control, respectively. F) Representative lifespan graphs for acute versus chronic treatment 
(connected Table S1, Supporting Information).
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significantly increased, which was not observed upon chronic 
treatment (Figure 1D). We quantified the pumping rate of 
the pharynx, which is the feeding apparatus in C. elegans that 
is controlled by neuro-muscular activity.[42] None of the treat-
ment paradigms significantly affected pharyngeal pumping 
behavior (Figure 1E). The nematode is a well-established model 
system to study the genetic and molecular mechanisms of the 
ageing process.[43] We monitored lifespan after acute or chronic 
treatment and found that GO exposure did not significantly 
influence longevity. However, in every second experiment we 
detected a small but significant lifespan extension in animals 
that were treated with GONH2 (Figure 1F; 1 out of 2 experi-
ments in acute treatment, 2 out of 4 experiments in chronic 
treatment), while the accumulated summary of all experi-
ments did not show a significant difference between treatments 
(Table S1, Supporting Information).
Taken together, our results indicate that chronic GO expo-
sure throughout the developmental process of C. elegans can 
lead to adverse effects on fecundity and animal size, which 
are not observed upon treatment with functionalized GONH2. 
Acute treatment does not result in a significant decline in any 
of the measured behavioral readouts.
2.3. Acute GO Exposure Results in a Transcriptional Induction 
of Genes Acting in the Innate Immune Response
To assess the effects of graphene on gene expression we performed 
RNA-Seq for transcriptome profiling upon acute treatment with 
GO or GONH2 (see the Experimental Section). In total, 231 genes 
were differentially regulated (FC ≥ ±1.2) upon GO exposure, while 
GONH2 affected the expression levels of 89 genes, and 83 genes 
were similarly affected by exposure to either material (Figure 2A; 
Tables S2 and S3, Supporting Information). We identified that dif-
ferential expression of genes that act in innate immunity, or in the 
defense response to gram-negative or gram-positive bacteria was 
overrepresented upon GO treatment (at least 55 genes), and to a 
lesser extend upon exposure to GONH2 (20 genes; Figure 2B,C). 
Analysis of the data sets showed that the fold changes in expres-
sion levels were relatively small but the differential expression was 
highly significant across replicates (Figure 2C). We validated 
gene expression levels by reverse transcriptase-quantitative 
polymerase chain reaction (RT-qPCR), focusing on a subset of 
innate immunity genes, which were differentially changed in 
both GO and GONH2 RNA-sequencing (RNA-Seq) data sets 
(Figure S3, Tables S4 and S5, Supporting Information).
The significant differential regulation of innate immunity 
genes upon GO treatment prompted us to investigate a possible 
correlation to previously obtained gene expression data sets on 
pathogen infection in C. elegans. The nematode is a well-estab-
lished model to study host-pathogen interaction and the effects 
on organismal stress responses and innate immunity.[30,44] 
Exposure to the human opportunistic pathogen Pseudomonas 
aeruginosa (PA14) causes a strong PMK-1 dependent transcrip-
tional response that correlates with gene expression changes 
caused by other pathogens, bacterial toxins or heavy metals.[45] 
Based on our RNA-Seq data, genes that have significantly 
altered gene expression upon GO treatment show a significant 
positive Pearson product-moment correlation with genes that 
are differentially expressed upon PA14 exposure (r = 0.2719412, 
p = 2.196 × 10−7; Figure 2D). The correlation of data obtained 
from GONH2-exposed animals with PA14 treatment-derived 
data was less pronounced, and less significant (r = 0.1462944, 
p = 0.006036; Figure 2D). Together, the RNA-Seq analysis shows 
that GO triggers a, compared to pathogen infection, relatively 
mild, but highly significant induction of innate immune gene 
expression, which is further reduced upon exposure to GONH2.
2.4. Innate Immune Defects Increase Sensitivity  
to GO Exposure
The innate immune response to a variety of pathogens 
in C. elegans is governed by the activity of the PMK-1 p38 MAP 
kinase pathway.[46] Parallel functions in pathogen resistance have 
been described for the MPK-1 ERK MAP kinase pathway and 
the mammalian hormone receptor homolog FSHR-1, amongst 
others.[47,48] Based on the observation that the innate immune 
response was transcriptionally activated upon graphene exposure 
(Figure 2), we exposed pmk-1, mpk-1, and fshr-1 deficient animals 
chronically to GO or GONH2 and assessed the pumping rates. 
Loss of pmk-1 resulted in a significant reduction of pumping 
behaviour upon GO exposure, while mpk-1 and fshr-1 mutants 
were unaffected (Figure S4A, Supporting Information).
In addition to its prominent role in pathogen defense, 
PMK-1 also responds to heat stress.[49] When pmk-1 mutants 
were chronically treated at the stressful temperature (25 °C) we 
detected a robust reduction of pumping rates upon GO expo-
sure, but not GONH2 (Figure 3A). Acute treatment at optimal 
growth temperature marginally reduced the pumping rates but 
the differences were not statistically significant (Figure S4B, 
Supporting Information). The mpk-1 mutant we used carries a 
temperature sensitive (ts) allele (ga111) but when grown at the 
restrictive temperature of 25 °C we did not detect any effects 
on the pumping rate upon graphene exposure (Figure 3A). The 
reduction in pumping rates measured in pmk-1 mutants chron-
ically exposed to GO at 25 °C went along with morphological 
decline in the pharyngeal pumping apparatus and the intestine 
(Figure 3B). Further, the animals developed a severe facultative 
vivipary (or “bagging”) phenotype, causing internal hatching 
of the embryos, followed by consuming the parent (Figure S5 
(Supporting Information); wild type: control 0%, GO 7.5 ± 5%, 
GONH2 0%; pmk-1(km25): control 10 ± 5%, GO 80 ± 10%, 
GONH2 22.5 ± 7.5%; n = 25). The size reduction that we had 
already observed in wild type animals was further enhanced in 
GO-treated pmk-1 mutants (Figure 3C). Under the same condi-
tions, we detected a significantly reduced locomotion behavior 
(Figure S6, Supporting Information). Those phenotypes were 
significantly less pronounced upon chronic GONH2 treatment. 
Conversely, chronic GO treatment at 25 °C did not shorten the 
lifespan of pmk-1 mutants below the respective control but led 
to a slight lifespan extension (2 out of 3 replicates), when bag-
ging animals were censored from the population to begin with. 
Under the same conditions, the wild type lifespan stayed unaf-
fected from GO or GONH2 treatment (Figure 3D).
C. elegans survival is severely shortened by PA14 exposure, 
involving an infection-like process when grown on minimal 
medium (“slow” killing assay).[50] On the background of the 
Small 2019, 15, 1902699
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elevated innate immune response observed upon GO-treat-
ment we were curious to see whether GO or GONH2 might 
alter pathogen-resistance. We found that chronic GO-exposure 
prior to growth on PA14 decreased C. elegans survival on the 
pathogen, which was not the case upon GONH2 treatment 
(Figure 3E; Table S6, Supporting Information). Expectedly, 
pmk-1 mutants were more sensitive to PA14 but, surprisingly, 
were slightly but significantly protected from pathogen infec-
tion when pretreated with GO, but not GONH2 (Figure 3E; 
Table S6, Supporting Information).
2.5. Germline-Less Mutants are Protected from GO Toxicity
The C. elegans germline plays an important role in the somatic 
stress response and longevity.[51,52] As mentioned above, 
chronic GO treatment leads to a severe bagging phenotype in 
pmk-1 mutants (Figure S5, Supporting Information). Bagging 
negatively affects reproductive fitness and survival of C. elegans 
and is induced when animals are grown in liquid culture, upon 
starvation conditions, or upon exposure to toxic chemicals or 
pathogens.[53–56] In contrast, laser-assisted germline depletion 
or genetic mutations that interrupt germ-cell proliferation 
increase C. elegans longevity and the activity of stress response 
pathways, including resistance to pathogen infection.[51,57] We 
speculated that removal of the germline will avert GO-induced 
bagging and, consequently, might increase tolerance to gra-
phene toxicity.
To test our hypothesis we crossed pmk-1 mutants with ani-
mals carrying mpk-1(ga111) allele, in which germline devel-
opment and offspring production are impaired when grown 
at the nonpermissive temperature (25 °C), and determined 
Small 2019, 15, 1902699
Figure 2. Acute treatment leads to a mild induction of genes involved in stress response/innate immunity. A) Venn diagram indicating the total number 
of genes differentially regulated upon acute GO or GONH2 exposure at 20 °C. B) Number of genes acting in specific biological processes that are 
differentially regulated upon acute GO or GONH2 exposure. C) Volcano blot showing log2(FC) of genes that are upregulated (red) or downregulated 
(blue) with an FC ≥ 1.2, versus the significance of differential regulation given by −log10(p value) upon GO or GONH2 treatment. Genes that act in 
the innate immune response are labeled (connected Figure S3, Supporting Information). D) Diagram showing the correlation between RNA-Seq data 
obtained from acutely treated animals with GO (left panel) or GONH2 (right panel), respectively, with Affymetrix microarray data from animals exposed 
for 4 h to PA14. Orange, genes upregulated; blue, genes downregulated; red, genes upregulated in both data sets; green, genes downregulated in both 
data sets; black, genes significantly changed, but below FC ± 1.2. The gray line indicates the correlation between the data sets. The Pearson correlation 
coefficient and p-value for significance of the correlation are indicated in the graph.
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that pharyngeal pumping rates upon chronic GO exposure 
were unaffected (Figure 4A).[58] Similarly, reduced pumping 
rates upon chronic GO treatment in pmk-1 mutants were 
restored to control levels when animals additionally lagged 
GLP-1, member of the LIN-12/Notch family of receptors that 
controls germline proliferation (Figure 4B).[59] In summary, 
when germline development and, consequently, offspring 
production are genetically suppressed, innate immune defi-
cient pmk-1 mutants display increased tolerance toward GO 
exposure.
3. Conclusion
C. elegans has emerged as a powerful model organism to quan-
titatively assess the molecular mechanisms underlying the tox-
icity of environmental toxins and nanoparticles.[27,60,61] In this 
study, we measured the adverse effects of GO and GONH2 upon 
acute or chronic exposure on various behavioral traits. Fecundity 
was reduced upon chronic GO exposure, confirming studies in 
C. elegans using GO material based on a different protocol.[62] 
However, the embryonic hatching rate stayed unaffected, while 
Small 2019, 15, 1902699
Figure 3. Chronic GO treatment affects the physiology of innate immune response defective pmk-1 mutants. A) Pumping rates measured in wild 
type, pmk-1(km25), and mpk-1(ga111) mutants. Animals were reared at 25 °C (nonpermissive temperature). We used unpaired Mann–Whitney 
test to analyze the results, with ****p < 0.0001 (connected Figure S4, Supporting Information). B) Representative images of the head region 
of animals after chronic treatment at 25 °C. Red arrows indicate morphological abnormalities in the proximal intestine and pharynx. Size bars 
correspond to 50 µm (connected Figure S5, Supporting Information). C) Animal size (perimeter) measured upon chronic treatment at 25 °C. 
Statistical analysis were performed with the Mann–Whitney test with **p < 0.01 and ****p < 0.0001. D) Representative lifespan result of wild 
type and pmk-1 mutants (connected Table S1, Supporting Information). E) Representative PA14 pathogen slow killing assay after 72 h of GO or 
GONH2 treatment. For statistical analysis compare Table S5 (Supporting Information), which contains the logrank (Mantel–Cox) test and the 
Gehan–Breslow–Wilcoxon test.
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facultative vivipary was induced homogeneously throughout a 
chronically treated population of pmk-1 mutants. Bagging has 
been defined as life-history trait in C. elegans: it is induced upon 
environmental stress to ensure the survival of progeny.[54] Our 
treatment paradigm combines stress through elevated tem-
perature (25 °C),[63] liquid culture rearing, and graphene expo-
sure in a stress response deficient pmk-1 mutant, leading to a 
synergistic toxicity effect that results in severe bagging. Genetic 
removal of the germline counteracted this deficit, allowing the 
interpretation that GO might negatively impact on somatic ger-
mline development. This could indicate that GO distributes 
systemically in the animal with the potential of damaging any 
other cell type, as it has been suggested for GO materials pro-
duced via the same method but with different lateral size distri-
bution and chemical functionalization.[64]
Chronic GO exposure led to a significantly decreased animal 
size and we detected morphological abnormalities in the 
pharynx and the intestine. Indeed, GO material can penetrate 
and degrade bacterial and eukaryotic cell membranes, and it has 
been suggested to breach the C. elegans intestinal barrier.[65–67] 
In fact, nematode cells might be particularly susceptible to GO, 
as they contain a high cholesterol content, and GO has been 
shown to oxidize cholesterol and to perturb plasma membrane 
lipid formation.[19] Hence, physical damage to the feeding appa-
ratus and the intestine could account for the smaller body size, 
as reduced food intake and the resulting metabolic changes cor-
relate with decreased animal length.[68]
Strikingly, egg-laying and body size were the only parame-
ters that were changed upon chronic exposure, while develop-
mental timing, pharyngeal pumping, locomotion, and lifespan 
(bagging animals were censored from the population) stayed 
unaffected, which stands in contrast to previous GO toxicity 
studies in C. elegans.[34,65,69] This discrepancy can be explained 
by differences between the physicochemical characteristics of 
GO, which has half the lateral size as compared to our study.
Acute treatment did not result in any defects in the measured 
phenotypes but, curiously, we detected a mobility increase. This 
trait could be an aversion response, or fight-and-flight response, 
similarly observed upon exposure to pathogenic bacteria,[70] 
indicating that worms can sense GO material.[71] The C. elegans 
intestine acts as a barrier to environmental toxins, metals, 
nanomaterials or pathogens,[46,65,72] and it is instrumental for 
implementing a systemic innate immune response.[73] Our 
genome-wide RNA-Seq data of acutely GO-treated animals 
showed an induced expression of innate immune response 
genes, which significantly, albeit mildly positive correlated with 
gene expression data obtained from C. elegans that encountered 
pathogenic PA14 bacteria.[45] Moreover, we found that animals 
lagging PMK-1 displayed elevated sensitivity to GO, corrobo-
rating previous findings in C. elegans that employed different-
source GO material.[74] We speculated that GO-exposure could 
immunize C. elegans to better tolerate a subsequent lethal path-
ogen exposure, which would indicate the in vivo outcome of a 
successfully mounted innate immune response. However, the 
detrimental effects were additive (Figure 3E), suggesting that 
GO-exposure causes cellular or organismal stress that goes 
beyond the defense capacity of innate immune responses. GO 
has been shown to induce oxidative stress and cytotoxicity in 
human cells and C. elegans, which is attributable to surface-
bound endoperoxide groups.[65,75]
Overall, our results confirm the notion of previous studies 
that attribute toxic effects of varying intensity to chronic GO 
exposure in C. elegans, underlining the need for the design 
of functionalized GO with improved biocompatibility. Previ-
ously, we demonstrated that the amino-functionalization of GO 
changes the impact on human immune cells: while GO triggers 
an extensive, non-cell-specific cytokine production throughout 
cell populations, GONH2 causes a much more specific, polar-
ized Th1 response, which has been implicated in counteracting 
cancer development.[26] In this study, GONH2 exposure did not 
cause any measurable detrimental effects in C. elegans for the 
quantified parameters; innate immune induction was consid-
erably lower, and pmk-1 mutants were not negatively affected 
by GONH2. Curiously, we detected a slight but significant 
lifespan extension of GONH2 treated animals. Moderate activa-
tion of stress response pathways, including the innate immune 
Small 2019, 15, 1902699
Figure 4. Genetic germline depletion protects pmk-1 mutants from toxic 
GO effects. A) Pumping rates measured in germline-deficient pmk-1;mpk-1 
double mutants compared to the respective controls. B) Pumping rates 
of the germline-less pmk-1;glp-1 double mutants. Both experiments in 
(A) and (B) were performed at 25 °C (nonpermissive temperature). 
Mann–Whitney test was used to measure statistical significance, with 
*p < 0.05, **p < 0.01 and ****p < 0.0001.
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response, can increase cellular stress tolerance and extend health 
and lifespan through a process called hormesis that has been 
demonstrated for numerous examples in the nematode.[76,77]
In conclusion, we present a comprehensive assessment 
of GO toxicity in C. elegans upon acute or chronic exposure. 
While the latter causes decreased fecundity and reduced animal 
size, acute treatment does not result in major health deficits. 
Our RNA-Seq data resolve that acute exposure to GO triggers 
an innate immune response that is, in comparison, robustly 
decreased in GONH2 treated animals. This study demonstrates 
the elevated biocompatibility of amino-functionalized GO in a 
whole-animal context, laying the foundation for future develop-
ment and convenient in vivo testing of graphene-based nano-
medical tools for diagnostics and therapeutics.
4. Experimental Section
Instruments for GO Characterization: Thermogravimetric analyses (TGA) 
were performed on a TGA1 (Mettler Toledo) apparatus from 30 to 900 °C 
with a ramp of 10 °C min−1 under N2 using a flow rate of 50 mL min−1 
and platinum pans. Infrared spectra were recorded using a Nicolet 
6700 FT-IR spectrometer (ThermoFisher). The samples were analyzed 
as dry KBr pellets. XPS analyses were performed on a Thermo Scientific 
K-Alpha X-ray photoelectron spectrometer with a basic chamber pressure 
of 10−8–10−9 bar with an anode using Al Kα radiation (hu = 1486.6 eV). 
The C (1s) photoelectron binding energy was set at 284.5 ± 0.2 eV and 
used as reference for calibrating the other peak positions. The samples 
were analyzed as a powder. Spot size of 400 µm was used. The survey 
spectra are average of 10 scans with a pass-energy of 200.00 eV and a 
step size of 1 eV. An ion gun was turned on during analysis. For each 
sample the analysis was repeated three times. TEM images were 
recorded using a Hitachi 7500 transmission electron microscope (Hitachi 
High Technologies Corporation, Tokyo, Japan) equipped with an AMT 
Hamamatsu digital camera (Hamamatsu Photonics, Hamamatsu City, 
Japan). Samples for AFM measurements were prepared by spin coating 
GO solutions on freshly cleaned SiO2/Si substrates. Images were 
acquired with a commercial microscope Multimode 8 (Bruker) operated 
in the tapping mode under ambient conditions. The average size of GO 
flakes was measured by automatic image processing.[78]
GO Functionalization: A volume of 77 µL (77 mg, 0.52 mmol) 2,2 
(ethylenedioxy)bis(ethylamine) was added under vigorous stirring to 
25 mL of a dispersion of GO (1.5 mg mL−1, 37.5 mg) in Milli-Q water. 
The reaction mixture was stirred for 3 d. After centrifugation (5000 rpm, 
30 min), the precipitate was dispersed in water and the crude was 
purified via dialysis against water (Spectra/Por dialysis membrane 
MWCO 12 000–14 000 Da) for 3 d. The number of amino groups was 
determined by the Kaiser test.[38] This colorimetric test is commonly used 
in peptide synthesis for the qualitative and quantitative determination 
of amine functions. The Kaiser test is based on the reaction of amines 
with ninhydrine, leading to the formation of a chromophoric compound 
whose concentration can be determined using UV–vis spectroscopy.
C. elegans Maintenance: C. elegans strains were maintained and 
propagated on OP50 E. coli seeded nematode growth medium (NGM) 
at 20 °C according to standard conditions, if not described otherwise.[79] 
The following strains were obtained from Caenorhabditis Genetics Center 
(CGC, Minneapolis, MN, USA): N2, Bristol C. elegans wild isolate; 
KU25 [pmk-1(km25) IV]; SD939 [mpk-1(ga111) unc-79(e1068) III]; 
CB4037 [glp-1(e2141) IV]; RB911 [fshr-1(ok778) V]. The following crosses 
were used for this study: pmk-1(km25);mpk-1(ga111);unc-79(e1068), 
glp-1(e2144);pmk-1(km25).
Bleach Synchronization of C. elegans: To obtain an L1 stage-
synchronized C. elegans population, worms and eggs were washed 
off NGM plates using 5 mL of M9 buffer (3 g KH2PO4, 6 g Na2HPO4, 
5 g NaCl in ddH2O, autoclaved, then supplemented with 1 × 10−3 m 
MgSO4). Worms were gently scraped off the plates with cell scrapers 
(VWR) and transferred into 15 mL centrifuge tubes (Falcon). Then 1 mL 
bleaching solution (5 m NaOH, sodium hypochloride solution ≈10%, 1:1 
mixture, Aldrich) was added and incubated for 5 min while continuously 
vortexing. Worms were then washed three times by centrifugation 
at 2800 rpm for 1 min at 20 °C (Centrifuge 5810R, Eppendorf) and 
replacing the supernatant with fresh M9 buffer. After the last washing 
step, ampicillin (stock solution 100 mg mL−1 in H2O) was added to the 
M9 buffer in a 1:1000 ratio. Eggs were incubated in 15 mL centrifuge 
tubes overnight (16–17 h) at room temperature (RT) on a rotating 
mixer (35 rpm) and hatched animals were pelleted the next day by 
centrifugation for 1 min at 1300 rpm. After removing the supernatant to 
about 1 mL, the number of hatched animals in a representative volume 
(3 µL) was determined at a Stereomicroscope (Leica M80).
Acute and Chronic GO Exposure in Liquid Culture: The L1 staged 
populations were pelleted by centrifugation at 1300 rpm for 1 min and 
resuspended in 2 mL K-medium (2.36 g KCl, 3 g NaCl in 1 L ddH2O, 
autoclaved). The wells of a 24-well plate were prepared by adding 
100 µL of a 1:250 suspension of cholesterol (5 mg mL−1 in EtOH) 
in sterile K-Medium (cholesterol is part of the standard C. elegans 
growth medium, as nematodes are auxotrophic for sterols), 100 µL 
of 50× concentrated E. coli OP50 culture with an OD of 0.9, pelleted 
by centrifugation (Centrifuge 5810R, Eppendorf) and resuspended 
in K-Medium, and 200 µL K-Medium. A volume of GO or GONH2 
suspension in ddH2O was added to a final concentration of 100 µg 
mL−1 solution per well as the experimental standard condition, while no 
material was added to the control wells. An adjusted volume containing 
300–400 worms suspended in K-medium was then added, bringing the 
final volume to 400 µL per well. Experiments were set up in triplicates 
per strain and condition. Unused wells were filled up with ddH2O and 
the 24-well plate was sealed with parafilm and placed in a closed plastic 
box together with wet paper towels to prevent the wells from drying 
out during prolonged incubation periods. For chronic treatments, 
animals were incubated for 72 h at the standard C. elegans culturing 
temperature of 20–22 °C, or at 25 °C, while shaking at 120 rpm. For 
the acute treatment, synchronized L1-larvae populations were grown on 
NGM plates seeded with OP50 into the L4 larval stage, then rinsed with 
K-Medium into a 15 mL Falcon tube (≈60 h after seeding), washed in 
K-Medium by letting the worms settle through gravity and removing the 
supernatant, and finally the suspension volume was adjusted to 2 mL 
with K-Medium. After determination of animal density by drop counting 
at the stereomicroscope, 300–400 animals were added to each well and 
incubated at 20–22 °C for 12 h while shaking at 120 rpm. After acute 
or chronic exposure, animals were washed once, transferred to OP50 
seeded NGM plates, and allowed to recover for 4 h. Worms were then 
picked from these plates for further assays and toxicity assessments.
Egglaying and Hatching Rate Assay: To assess fertility upon graphene 
treatment, three gravid adult worms were transferred to OP50 seeded 
NGM plates and allowed to lay eggs for 3 h (in quadruplets). Then the 
adults were removed and eggs were counted right after. The hatching 
rate of the laid eggs was determined by counting the larvae 24 h later.
Quantification of Development Stages: The worms were screened for 
developmental defects after graphene treatment by transferring about 
100 individuals per strain to separate 3.5 cm OP50 seeded NGM plates. 
Representative Images were taken of each plate at 14-fold magnification 
using an Axio Zoom-V16 Stereomicroscope with camera at the indicated 
time points (12, 48, and 72 h after treatment). The number of worms on 
each plate of was determined in silico by using the “Cell Counter” plugin 
(written by Kurt De Vos, University of Sheffield, Academic Neurology) 
implemented in the ImageJ software.
Pharyngeal Pumping Rate Assay: 20 worms per strain and treatment 
condition were transferred to a fresh OP50 seeded NGM plate and 
pumping rates were measured by counting pharyngeal contraction in 
30 s timeframes using a high-resolution Stereomicroscope (Zeiss, Axio 
Zoom-V16).
Locomotion Assay: About 50–100 worms per strain and treatment 
condition were transferred to an OP50 seeded NGM plate. Movements 
of the worms were recorded for 30 s with 14 frames s−1 using an Axio 
Small 2019, 15, 1902699
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Zoom-V16 Stereomicroscope with camera at tenfold magnification. 
Average and maximum movement speed, distance covered by animal 
from start to finish, sum of length of all movement vectors, and length 
of the average perimeter (outline) of each recorded worm were assessed 
using the “wrMTrck” plugin implemented in the ImageJ software.[41] 
Data were averaged and plotted for each strain and condition.
Lifespan Assay: Lifespan was assessed starting at young adult stage 
after recovery from liquid GO or GONH2 treatment. 150 healthy worms 
that did not display a bagging phenotype, per strain and condition, were 
equally distributed on 10 OP50 seeded NGM plates and scored for death 
events at least every second day until all worms were dead. Worms were 
transferred to fresh OP50 seeded NGM plates at each scoring time point 
during their fertile lifespan. Animals were censored if I) they could not 
be localized, II) died after crawling off the agar surface or immersed 
into the agar, or III) displayed bagging. All death events over time for 
each strain and condition were summarized in a final lifespan curve and 
statistics were performed through the Graphpad Prism software.
RNA Isolation for RT-qPCR and RNA-Seq: Total RNA for RT-qPCR 
was extracted from 100 worms per strain and condition, and for 
RNA-Seq from 500 worms per strain and condition, after 4 h of recovery 
following liquid culture. Worms were transferred into 50 µL M9 buffer, 
subsequently 1 mL Trizol was added and the solution was frozen at 
−80 °C. Samples were then thawed, transferred into homogenizer vials 
(Peqlab/VWR, 91-PCS-TV and 91-PCS-TC) filled up to 0.5 cm with beads 
(Zirconia/Glas-Beads, Carl Roth) and homogenized at 6000 rpm for two 
times 20 s with 30 s pause using a Precellys Lyser (Peqlab). After 5 min 
of incubation at RT, 100 µL BCP was added and samples vortexed for 
15 s, followed by 2 min incubation at RT. Samples were centrifuged for 
15 min at 12 000 rcf at 4 °C and upper clear phase was transferred into 
a new 1.5 mL reaction tube. RNA was isolated using the Qiagen RNeasy 
Mini Kit (Qiagen), eluted in 30 µL RNase free H2O, and processed for 
RNA-Seq with an Illumina HiSeq4000. For reverse-transcription, RNA 
was diluted to 1 µg in 11.5 µL total volume, incubated at 70 °C for 2 min 
and subsequently chilled on ice. For cDNA synthesis, 8.5 µL reverse-
transcription master mix (4 µL 5× First-Strand Buffer [Invitrogen], 
2 µL 0.1 m DTT [Invitrogen], 1 µL dNTPs, 1 µL 50 × 10−6 m oligio dTs 
[Invitrogen], 0.5 µL Superscript III RT enzyme [Invitrogen]) was added 
to each sample and incubated for 1.5 h at 42 °C followed by 5 min 
incubation at 92 °C. To adjust the cDNA volume to 100 µL, 80 µL ddH2O 
was added and the cDNA was directly used for qPCR or stored at −20 °C. 
Real-time qPCR was performed using Platinum Taq (Invitrogen) for 
amplification and SYBR Green (Sigma Aldrich) for detection. Reactions 
were carried out in 96-well qPCR plates (Bioplastics) covered with 
plate sealing film (Biorad). Real-time qPCR was run at the optimized 
annealing temperature of 58 °C. Used primers for target and reference 
genes are listed in Table S5 (Supporting Information). All reactions were 
performed in triplicate. Relative quantification of each of three target 
gene replicate in comparison to each of three replicates of five reference 
genes was determined and with the obtained values the averaged ratios 
between target gene and reference gene expression were calculated 
considering all 5 reference genes.
RNA-Seq Data Analysis: The data files were deposited under the 
GEO accession code GSE131070. Data were processed through the 
QuickNGS pipeline,[80] Ensembl version 93. Reads were mapped to 
the C. elegans genome using Tophat (version 2.0.10) and abundance 
estimation was performed with Cufflinks (Version 2.1.1). DESeq2 was 
used for differential gene expression analysis. The results were uploaded 
into the QuickNGS database. Microarray data was analyzed by using 
Affymatrix Power Tools (version 1.15.1), which was applied to subtract 
the background, normalization and summarizing expression probe 
data from the CEL files. To calculate the differential expression and the 
q values, R-packages were used, including ggplot2 for the correlation 
analysis between RNA-Seq and Affymetrix data.
Slow Killing Assay: Four days before assay start Pseudomonas 
aeruginosa strain PA14 was freshly streaked from a frozen stock on LB 
agar, incubated at 37 °C for 12–18 h overnight and subsequently shifted 
to 4 °C. Two days before the assay start 15 mL LB liquid medium was 
inoculated with a PA14 colony and incubated for 12–16 h overnight. 
The same day, slow killing plates were prepared by mixing 3.5 g 
Bacto-Peptone, 3 g NaCl, and 17 g Bacto(Serva)-Agar in 1 L ddH2O, 
autoclaving, adding of 1 mL 1 m MgSO4, 25 mL 1 m KH2PO4 (pH 6), 
1 mL of 1 m CaCl2, and 1 mL of 5 mg mL−1 cholesterol in ethanol after 
the medium was chilled to 55 °C and subsequently SK medium was 
poured into 3.5 cm sterile Petri dishes. Plates were stored at 4 °C after 
drying at RT overnight. One day before assay start, 10 µL of overnight 
grown PA14 culture was added to each SK plate and spread into ≈1 cm² 
squares in the middle of the plates using a sterile cell scraper. PA14 
seeded SK plates were left to dry at RT for 20 min before incubation 
at 37 °C for 24 h. To start the experiment, 40 pretreated worms were 
picked on an SK plate and shifted to 25 °C. The experiment was set up 
in triplicates and scored at the indicated time points. Censoring was 
performed according to the lifespan assay protocol. Surviving animals 
were transferred to the empty PA14 seeded SK plates in a 24 h rhythm to 
avoid crowding by the offspring population.
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